Octapharma announces approval of new Nuwiq® product strengths in Europe, increasing dosing flexibility for patients with haemophilia A
Lachen, Switzerland 18 June 2018: Octapharma announced today that the European Medicines Agency (EMA) has approved an extension of marketing authorisation for its human cell line-derived recombinant factor VIII (rFVIII)...
Octapharma share promising preclinical data for SubQ-8, a novel subcutaneous recombinant FVIII, at WFH 2018
Lachen, Switzerland 28 May 2018: Octapharma announced today that pre-clinical data for SubQ-8 were presented during a symposium at the recent World Federation of Hemophilia (WFH) 2018 World Congress in Glasgow, UK. SubQ-8,...
Octapharma present new data on the benefits of Nuwiq® in patients with haemophilia A at the World Federation of Hemophilia 2018 World Congress
Lachen, Switzerland 28 May 2018: Octapharma announced today that new data on the benefits of Nuwiq® in patients with haemophilia A were presented during a symposium at the recent World Federation of Hemophilia (WFH) 2018 World...
Interested Camp Professionals Should Apply by May 30th for Grant Funded Program
Chris Bombardier, First Hemophiliac to Climb the Seven Summits, Joins Octapharma USA at HFA Annual Symposium in Cleveland
Mountain Climber Will Discuss Mount Everest Climb, Upcoming Documentary One-on-One With Visitors of Octapharma Booth
‘Making the Connection’ will be held June 22 – 25 in Palm Beach Gardens, Florida
Octapharma Group publishes 2017 annual results reporting revenue of €1.72 billion and operating income of €349 million
Lachen, Switzerland, March 1st, 2018: Over the last six years, the Octapharma Group has accomplished a remarkable compound annual growth rate of 15% and reports another record-breaking result for 2017, with sales of €1.72 billion...